<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562328</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000574754</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0785</secondary_id>
    <secondary_id>U4449s</secondary_id>
    <secondary_id>001.0888</secondary_id>
    <secondary_id>07-002087</secondary_id>
    <nct_id>NCT00562328</nct_id>
  </id_info>
  <brief_title>Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Antibody Therapy With Alemtuzumab, Rituximab and GM-CSF for Initial Treatment of High Risk Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth&#xD;
      in different ways. Some block the ability of cancer cells to grow and spread. Others find&#xD;
      cancer cells and help kill them or carry cancer-killing substances to them.&#xD;
      Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in&#xD;
      bone marrow or peripheral blood. Giving monoclonal antibody therapy together with GM-CSF may&#xD;
      be an effective treatment for early-stage chronic lymphocytic leukemia.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of giving rituximab and alemtuzumab&#xD;
      together with GM-CSF and to see how well it works in treating patients with early-stage&#xD;
      chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the rate of complete and overall response in patients with high-risk,&#xD;
           early-stage, chronic lymphocytic leukemia (CLL) treated with alemtuzumab, rituximab, and&#xD;
           sargramostim (GM-CSF).&#xD;
&#xD;
        -  To monitor and assess toxicity of this regimen in these patients through clinical&#xD;
           evaluation and serial monitoring of cytomegalovirus antigenemia by polymerase chain&#xD;
           reaction (PCR).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the overall and progression-free survival, time to response, time to next&#xD;
           treatment, and duration of response in patients treated with this regimen.&#xD;
&#xD;
        -  To assess the correlation between individual prognostic markers (i.e., 17p-, 11q-,&#xD;
           unmutated VH gene, use of VH3-21, ZAP70+, CD38+) and clinical outcome.&#xD;
&#xD;
      Correlative Studies&#xD;
&#xD;
        -  To assess response in these patients using an expanded definition of response, including&#xD;
           minimal residual disease (MRD) by sensitive flow cytometry in patients in complete&#xD;
           clinical remission.&#xD;
&#xD;
        -  To assess MRD status of responding patients using sensitive flow cytometry and molecular&#xD;
           assays (i.e., spectral karyotype analysis of CLL cells) before treatment and at relapse&#xD;
           to identify subpopulations that could contribute to disease resistance and relapse.&#xD;
&#xD;
        -  To detail the in vivo effect of this regimen on critical aspects of the immune system in&#xD;
           CLL.&#xD;
&#xD;
        -  To determine if GM-CSF, β-glucan, and CpG7909 can increase antibody dependent cellular&#xD;
           cytotoxicity to improve efficacy against CLL cells and clinical response to treatment.&#xD;
&#xD;
      OUTLINE: Patients receive rituximab IV over 30 minutes on day 3 of weeks 2-5, alemtuzumab&#xD;
      subcutaneously (SC) on days 3, 4, and 5 in week 1 and on days 1, 3, and 5 in weeks 2-5, and&#xD;
      sargramostim SC on days 1, 3, and 5 in weeks 1-6. Treatment continues in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo blood sample collection for measurement of serum cytomegalovirus DNA copy&#xD;
      number by polymerase chain reaction at baseline, weekly during treatment, and monthly for the&#xD;
      6 months after completion of treatment. Patients also undergo bone marrow biopsy and aspirate&#xD;
      at two months and then again at 12 months (if in complete remission). Blood samples are&#xD;
      collected periodically during study for evaluation of prognostic biomarkers (i.e., 11q-,&#xD;
      17p-, unmutated IgVH gene, VH3-21 gene segment use, and CD38 and ZAP-70 expression) by&#xD;
      fluorescent in situ hybridization (FISH) and for immunophenotyping by flow cytometry. Blood&#xD;
      samples are collected from patients at the Mayo Clinic Rochester site at baseline and&#xD;
      periodically during study for immunological and other correlative studies, including minimal&#xD;
      residual disease (in responding patients only).&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Actual">December 18, 2014</completion_date>
  <primary_completion_date type="Actual">February 5, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Response, as defined by the National Cancer Institute Working Group (NCIWG), requires the following for a period of at least 2 months:&#xD;
CR: no lymphadenopathy, hepatomegaly, splenomegaly or constitutional symptoms; normal complete blood count; confirmed by bone marrow (BM) aspirate &amp; biopsy&#xD;
PR: 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver/spleen size, presence/absence of constitutional symptoms; plus ≥1 of the following: ≥1500/μL polymorphonuclear leukocytes, &gt;100,000/μL platelets, &gt;11.0 g/dL hemoglobin or 50% improvement for these parameters without transfusions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Time from registration to progression (up to 5 years)</time_frame>
    <description>Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to the standard NCI-WG96 criteria. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>time from start of response to progression (up to 5 years)</time_frame>
    <description>Duration of response (DOR) is defined as the time from documentation of response (CR or PR) to disease progression. The median DOR with 95% CI was estimated using the Kaplan Meier method.Response, as defined by the National Cancer Institute Working Group (NCIWG), requires the following for a period of at least 2 months:&#xD;
CR: no lymphadenopathy, hepatomegaly, splenomegaly or constitutional symptoms; normal complete blood count; confirmed by bone marrow (BM) aspirate &amp; biopsy&#xD;
PR: 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver/spleen size, presence/absence of constitutional symptoms; plus ≥1 of the following: ≥1500/μL polymorphonuclear leukocytes, &gt;100,000/μL platelets, &gt;11.0 g/dL hemoglobin or 50% improvement for these parameters without transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Treatment</measure>
    <time_frame>time from end of protocol treatment to subsequent treatment (up to 5 years)</time_frame>
    <description>Time to next treatment was defined as the time from end of active (protocol) treatment to the start of subsequent treatment. The median and 95% CI was estimated using the Kaplan Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from registration to death (up to 5 years)</time_frame>
    <description>Overall Survival (OS) was defined as the time from registration to death of any cause. Participants were followed for a maximum of 5 years from registration. The median OS with 95% CI was estimated using the Kaplan Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab + Rituximab + GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alemtuzumab + Rituximab + GM-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Week 1 (dose escalation):&#xD;
Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously&#xD;
Weeks 2-5:&#xD;
30mg subcutaneously three times a week.</description>
    <arm_group_label>Alemtuzumab + Rituximab + GM-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Weeks 2-5:&#xD;
375 mg/m^2 by IV once weekly</description>
    <arm_group_label>Alemtuzumab + Rituximab + GM-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>Week 1-6:&#xD;
250 mcg subcutaneously three time as week</description>
    <arm_group_label>Alemtuzumab + Rituximab + GM-CSF</arm_group_label>
    <other_name>GM-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of chronic lymphocytic leukemia (CLL) meeting the following criteria:&#xD;
&#xD;
               -  Minimum threshold peripheral blood lymphocyte count 5 x 10^9/L&#xD;
&#xD;
               -  Monoclonality (light chain exclusion) of B lymphocytes detected by&#xD;
                  immunophenotyping (CD19-positive), demonstrating ≥ 3 of the following&#xD;
                  characteristics:&#xD;
&#xD;
                    -  CD5-positive&#xD;
&#xD;
                    -  CD23-positive&#xD;
&#xD;
                    -  Dim surface light chain expression&#xD;
&#xD;
                    -  Dim surface CD20 expression&#xD;
&#xD;
               -  Negative for IGH/CCND1 translocation AND/OR immunostaining is negative for cyclin&#xD;
                  D1 expression by fluorescent in-situ hybridization (FISH) analysis&#xD;
&#xD;
               -  Rai stage 0, I, or II disease that does not meet standard NCI-Working Group&#xD;
                  criteria for treatment of CLL&#xD;
&#xD;
          -  Poor prognosis as defined by ≥ 1 of the following factors:&#xD;
&#xD;
               -  Unmutated IgVH mutation status AND CD38 expression (i.e., ≥ 30% cells positive on&#xD;
                  flow cytometry)&#xD;
&#xD;
               -  Unmutated IgVH mutation status AND ZAP-70 expression (i.e., ≥ 20% cells positive&#xD;
                  on flow cytometry)&#xD;
&#xD;
               -  VH3-21 gene segment use irrespective of mutation status AND CD38 expression (≥&#xD;
                  30% cells positive on flow cytometry)&#xD;
&#xD;
               -  VH3-21 gene segment use irrespective of mutation status AND ZAP-70 expression (≥&#xD;
                  20% cells positive on flow cytometry)&#xD;
&#xD;
               -  11q-negative*&#xD;
&#xD;
               -  17p-negative* NOTE: *Determination of IgVH mutation status is not required in&#xD;
                  patients whose eligibility is based on 17p13- or 11q22- deletions&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0- 2&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 3.0 times ULN OR direct bilirubin ≤ 1.5 ULN&#xD;
&#xD;
          -  AST ≤ 3.0 times ULN (unless due to hemolysis or CLL)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must practice effective contraception&#xD;
&#xD;
          -  Willing to provide mandatory blood samples (for patients at the Mayo Clinic in&#xD;
             Rochester only) for research studies as required by the protocol&#xD;
&#xD;
          -  No comorbid conditions, including any of the following:&#xD;
&#xD;
               -  New York Heart Association Class III or IV heart disease&#xD;
&#xD;
               -  Myocardial infarction within the past month&#xD;
&#xD;
               -  Uncontrolled infection&#xD;
&#xD;
               -  HIV infection or AIDS&#xD;
&#xD;
               -  Serological evidence of active hepatitis B infection (i.e., serum antigen or&#xD;
                  e-antigen positivity) or positive hepatitis C serology&#xD;
&#xD;
          -  No other active primary malignancy requiring treatment or limiting survival to ≤ 2&#xD;
             years&#xD;
&#xD;
          -  No active autoimmune hemolytic anemia, immune thrombocytopenia, or pure red blood cell&#xD;
             aplasia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  No prior chemotherapy or monoclonal antibody treatment for CLL&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clive S. Zent, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2007</study_first_posted>
  <results_first_submitted>April 11, 2012</results_first_submitted>
  <results_first_submitted_qc>April 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2012</results_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage 0 chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty-three (33) participants were recruited at Mayo Clinic (Rochester and Arizona) between January 2008 and February 2010.</recruitment_details>
      <pre_assignment_details>All patients were deemed eligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alemtuzumab + Rituximab + GM-CSF</title>
          <description>Alemtuzumab + Rituximab + GM-CSF</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alemtuzumab + Rituximab + GM-CSF</title>
          <description>Alemtuzumab + Rituximab + GM-CSF</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="42" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rai Stage</title>
          <description>Rai staging is a way to categorize the disease progression of chronic lymphocytic leukemia (CLL); higher stages reflect increasing severity.&#xD;
Rai Stage 0: Lymphocytosis only, Rai Stage I: Lymphocytosis and lymphadenopathy, Rai Stage II: Lymphocytosis and hepatomegaly +/- splenomegaly, Rai Stage III: Lymphocytosis and anemia, Rai Stage IV: Lymphocytosis and thrombocytopenia</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD38 Expression Status</title>
          <description>This test is used to predict the rate of progression from diagnosis to need for treatment in CLL. Participants with positive CD38 (&gt;=30%) tend to experience a more aggressive course of CLL.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive (&gt;=30%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative (&lt;30%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Immunoglobulin Variable Heavy Chain (IGVH) Mutation Status</title>
          <description>IGVH testing helps predict which patients will experience a more aggressive (if the gene is unmutated, &lt;=2%) or less aggressive (if the gene is mutated, &gt;2%) course of CLL. This technically complex test is only available at select medical institutions.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mutated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unmutated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ZAP-70 Expression</title>
          <description>This test is used to predict the rate of progression from diagnosis to need for treatment in CLL. Participants with positive ZAP-70 (&gt;=20%) tend to experience a more aggressive course of CLL.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive (&gt;=20%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative (&lt;20%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months</title>
        <description>Response, as defined by the National Cancer Institute Working Group (NCIWG), requires the following for a period of at least 2 months:&#xD;
CR: no lymphadenopathy, hepatomegaly, splenomegaly or constitutional symptoms; normal complete blood count; confirmed by bone marrow (BM) aspirate &amp; biopsy&#xD;
PR: 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver/spleen size, presence/absence of constitutional symptoms; plus ≥1 of the following: ≥1500/μL polymorphonuclear leukocytes, &gt;100,000/μL platelets, &gt;11.0 g/dL hemoglobin or 50% improvement for these parameters without transfusions</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab + Rituximab + GM-CSF</title>
            <description>Patients received Alemtuzumab + Rituximab + GM-CSF.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months</title>
          <description>Response, as defined by the National Cancer Institute Working Group (NCIWG), requires the following for a period of at least 2 months:&#xD;
CR: no lymphadenopathy, hepatomegaly, splenomegaly or constitutional symptoms; normal complete blood count; confirmed by bone marrow (BM) aspirate &amp; biopsy&#xD;
PR: 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver/spleen size, presence/absence of constitutional symptoms; plus ≥1 of the following: ≥1500/μL polymorphonuclear leukocytes, &gt;100,000/μL platelets, &gt;11.0 g/dL hemoglobin or 50% improvement for these parameters without transfusions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to the standard NCI-WG96 criteria. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.</description>
        <time_frame>Time from registration to progression (up to 5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab + Rituximab + GM-CSF</title>
            <description>Patients received Alemtuzumab + Rituximab + GM-CSF.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to the standard NCI-WG96 criteria. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="9.4" upper_limit="NA">The 95% confidence interval upper limit was not yet reached (below the level of detection).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response (DOR) is defined as the time from documentation of response (CR or PR) to disease progression. The median DOR with 95% CI was estimated using the Kaplan Meier method.Response, as defined by the National Cancer Institute Working Group (NCIWG), requires the following for a period of at least 2 months:&#xD;
CR: no lymphadenopathy, hepatomegaly, splenomegaly or constitutional symptoms; normal complete blood count; confirmed by bone marrow (BM) aspirate &amp; biopsy&#xD;
PR: 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver/spleen size, presence/absence of constitutional symptoms; plus ≥1 of the following: ≥1500/μL polymorphonuclear leukocytes, &gt;100,000/μL platelets, &gt;11.0 g/dL hemoglobin or 50% improvement for these parameters without transfusions</description>
        <time_frame>time from start of response to progression (up to 5 years)</time_frame>
        <population>Only patients who responded to treatment are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab + Rituximab + GM-CSF</title>
            <description>Patients received Alemtuzumab + Rituximab + GM-CSF.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response (DOR) is defined as the time from documentation of response (CR or PR) to disease progression. The median DOR with 95% CI was estimated using the Kaplan Meier method.Response, as defined by the National Cancer Institute Working Group (NCIWG), requires the following for a period of at least 2 months:&#xD;
CR: no lymphadenopathy, hepatomegaly, splenomegaly or constitutional symptoms; normal complete blood count; confirmed by bone marrow (BM) aspirate &amp; biopsy&#xD;
PR: 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver/spleen size, presence/absence of constitutional symptoms; plus ≥1 of the following: ≥1500/μL polymorphonuclear leukocytes, &gt;100,000/μL platelets, &gt;11.0 g/dL hemoglobin or 50% improvement for these parameters without transfusions</description>
          <population>Only patients who responded to treatment are included in this analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="8.8" upper_limit="NA">The 95% confidence interval upper limit was not yet reached (below the level of detection).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Next Treatment</title>
        <description>Time to next treatment was defined as the time from end of active (protocol) treatment to the start of subsequent treatment. The median and 95% CI was estimated using the Kaplan Meier method.</description>
        <time_frame>time from end of protocol treatment to subsequent treatment (up to 5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab + Rituximab + GM-CSF</title>
            <description>Patients received Alemtuzumab + Rituximab + GM-CSF.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Next Treatment</title>
          <description>Time to next treatment was defined as the time from end of active (protocol) treatment to the start of subsequent treatment. The median and 95% CI was estimated using the Kaplan Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" lower_limit="25.5" upper_limit="NA">The 95% confidence interval upper limit was not yet reached (below the level of detection).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall Survival (OS) was defined as the time from registration to death of any cause. Participants were followed for a maximum of 5 years from registration. The median OS with 95% CI was estimated using the Kaplan Meier method.</description>
        <time_frame>Time from registration to death (up to 5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab + Rituximab + GM-CSF</title>
            <description>Patients received Alemtuzumab + Rituximab + GM-CSF.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival (OS) was defined as the time from registration to death of any cause. Participants were followed for a maximum of 5 years from registration. The median OS with 95% CI was estimated using the Kaplan Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% confidence interval for overall survival has not been reached (below the level of detection).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Alemtuzumab + Rituximab + GM-CSF</title>
          <description>Alemtuzumab + Rituximab + GM-CSF</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="43" subjects_affected="24" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Blood Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Lip infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Opportunisitic infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="16" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="59" subjects_affected="25" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Timothy G. Call, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-4671</phone>
      <email>Call.Timothy@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

